MSC-INHP-QHCP-1: Questioner to Health Care Professionals and Regulatory Authorities (Questioner to HCPs and RAs, Study MSC-INHP-8797)

Study type

• Study type:
  Not applicable
• Scope of the study:
  Drug utilisation
• If ‘Not applicable’, further details on the study type:
  Active surveillance

Study drug and medical condition

• Medical condition to be studied:
  HER2 positive breast cancer

  Colorectal cancer metastatic

  Glioblastoma

  Non-Hodgkin's lymphoma
• Additional medical condition(s):
  metastatic or recurrent non-small cell lung cancer,advanced (International Fede ration of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopi an tube, or primary peritoneal cancer

Population studied

• Age groups:
  • Children (2 to < 12 years)
  • Adolescents (12 to < 18 years)
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  1000

Study design details

• Main study objective:
  Study MSC-INHP-8797 addressed to health care professionals and regulatory authorities is to measure current and future standard care of cancer therapy and monitor patient outcome attributed by newly developed drugs such as Biosimilars.
• Data analysis plan:
  Epidemiological methods shall be used for the analysis of the collected data.